Learn when to order tissue, liquid, and RNA testing to find KRAS G12C in lung adenocarcinoma and start treatment fast despite delayed results.
Back
KRAS G12C-Mutated NSCLC: Identifying Patients, First-Line Immunotherapy Data, and Emerging RAS-Directed Agents
KRAS G12C-Mutated NSCLC: Identifying Patients, First-Line Immunotherapy Data, and Emerging RAS-Directed Agents
Episodes
All
All
Learn when to order tissue, liquid, and RNA testing to find KRAS G12C in lung adenocarcinoma and start treatment fast despite delayed results.
Advertisement
Advertisement
Trending on OncLive
1
Updated NCCN Guidelines Recommend Rusfertide Across Polycythemia Vera
2
Tegavivint Plus Osimertinib Shows Early Activity in First-Line EGFR-Mutated NSCLC
3
FDA Grants Final Approval to Lutetium Lu 177 Dotatate Biosimilar for SSTR+ GEP-NETs
4
FDA Approves Generic Lanreotide Injection for GEP-NETs
5